Related Experiment Video

Updated: Jun 17, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Arsenic trioxide inhibits cholangiocarcinoma cell growth and induces apoptosis

Fei Zhong1, Shineng Zhang, Chunkui Shao

  • 1Department of Medical Oncology, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.

Pathology Oncology Research : POR
|December 17, 2009
PubMed

Insights

Arsenic trioxide (As(2)O(3)) effectively inhibits human cholangiocarcinoma cell growth and triggers apoptosis. This occurs through mitochondria-mediated, caspase-dependent pathways, offering potential new cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Arsenic trioxide (As(2)O(3)) shows promise in treating various cancers.
  • Its effects on cholangiocarcinoma, a type of bile duct cancer, remain largely unexplored.

Purpose of the Study:

  • To investigate the impact of As(2)O(3) on human cholangiocarcinoma SK-ChA-1 cells.
  • To elucidate the underlying molecular mechanisms of As(2)O(3) in cholangiocarcinoma.

Main Methods:

  • Treatment of SK-ChA-1 cells with clinically relevant concentrations of As(2)O(3).
  • Assessment of cell viability, apoptosis induction, mitochondrial membrane potential (MMP), and protein expression (Bcl-2 family, PARP).
  • Evaluation of caspase activation (caspase-3, caspase-9) and Akt phosphorylation.

Main Results:

  • As(2)O(3) significantly inhibited cholangiocarcinoma cell growth and induced apoptosis.
  • Apoptosis involved the release of cytochrome C, decreased MMP, and activation of caspases.
  • As(2)O(3) treatment altered Bcl-2 family protein expression and inhibited Akt phosphorylation.

Conclusions:

  • As(2)O(3) induces apoptosis in cholangiocarcinoma cells via a mitochondria-mediated, caspase-dependent pathway.
  • Inhibition of Akt phosphorylation may contribute to As(2)O(3)'s anti-cancer effects in cholangiocarcinoma.
  • As(2)O(3) presents a potential therapeutic agent for cholangiocarcinoma treatment.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...